STS	Soft-tissue sarcomas
FNCLCC	French Federation of Cancer Centers Sarcoma Group
NCI	National Cancer Institute
ASIR	Age-standardised incidence rate
NED	No evidence of disease
SBRT	Stereotactic body radiotherapy
CINSARC	Complexity INdex in SARComas
TLS	Tertiary lymphoid structures
PD-1	Programmed cell death protein 1
ctDNA	Circulating tumour DNA
MRD	Minimal residual disease
TMB	Tumour mutational burden
PD-L1	Programmed death-ligand 1
UPS	Undifferentiated pleomorphic sarcoma
AJCC	American Joint Committee on Cancer
MSKCC	Memorial Sloan Kettering Cancer Center
PERSARC	Personalised Sarcoma Care
PFS	Progression-free survival
OS	Overall survival
DFI	Disease-free interval
SABR	Stereotactic ablative radiotherapy
TME	Tumour microenvironment
ICI	Immune checkpoint inhibitor
ICIs	Immune checkpoint inhibitors
CTLA-4	Cytotoxic T-lymphocyte antigen 4
DLTs	Definitive local therapies
AI	Artificial intelligence
ML	Machine learning
CT	Computed tomography
PET	Positron emission tomography
RNA-seq	RNA sequencing